ABSTRACT. Despite a preeminent role of epidermal Langerhans cells (LC) in inducing primary immunity, application of gene-based modification to LC function is limited by lack of well-defined transcription regulatory units that can direct LC-specific gene expr ession. Previously we reported that the promoter activity of a 5'-flanking region of the dectin-2 gene (Dec2FR) is highly targeted to epidermal LC of transgenic mice bearing a Dec2FR-driven Luc gene. Using the mice, in which transcription activity of Dec2FR is measured by Luc assays, presently we characterized regulation of Dec2FR activity in leukocyte subpopulations under resting and activation status. Luc activity was highly variable in LC isolated from different skin areas and detected in other DC subset (dermal DC) but the levels were much lower than in resting LC. Activation of leukocytes markedly up-regulated Luc activity in all four subpopulations (CD11c + splenic DC, Mac-1 high peritoneal macrophages, splenic B220 + B cells, and CD3 + T cells). However, these levels remained lower than those in the resting and activated LC. These findings indicate that dectin-2 promoter activity remains targeted to epidermal LC even after activation of leukocytes, suggesting a high potential of Dec2FR to engineer LC-targeted gene expression to heighten efficacy of genetic vaccination and to manipulate phenotypes of preexisting immunity (Th1 vs. Th2).
Dendritic cells (DC) including epidermal Langerhans cells (LC) are antigen presenting cells (APC) that are critical to immunity because of their unsurpassed potency in presenting antigens to naive T cells for the generation of primary cellular and humoral immune responses against viral, microbial, tumor-associated antigens, and even self-antigens [2, 20, 22] . Because of the critical function, DC have been regarded as a key target cell in cellular and/or genetic manipulations to augment their APC capacity (vaccination against tumors and infections) and also to regulate types of immune responses (Th1 vs. Th2 types) [3, 8, 25, 26] . Cellular manipulations (or DC-based vaccination) require large numbers of purified, syngeneic DC, in vitro pulsing DC with antigens and/or accessory molecules (e.g., cytokines) to amplify APC properties, and infusion of the modified APC back into the host [25] . Actually, these procedures are time-consuming and costly. On the other hand, genetic manipulation or DNA vaccination, in which immunization is performed simply by injection of naked DNA encoding antigens to hosts, certainly circumvents those disadvantages, but it cannot activate immune responses as efficiently as the former protocol.
Considerable effort has been directed to developing convenient methods to heighten the efficacy of genetic vaccination. Application of APC-targeting delivery of antigens to genetic vaccination has been proven to markedly improve the efficacy, with up to 10 5 -fold greater than non-targeted conventional vaccines [7, 13] : A non-tissue-specific promoter-driven gene was used for vaccination, which encodes a fusion protein consisting of CTLA-4 and an antigen, in which the CTLA-4 escorts the antigen to APC by its specific binding to co-stimulatory molecules, CD80 and CD86 predominantly expressed by APC [7] . However, an APC-targeting gene expression system has not been formally applied to the APC-targeting delivery of antigens because of lack of well-defined transcription units capable of initiating transcription of foreign genes in an APC or DC-specific manner.
Previously we identified a novel gene (termed dectin-2) [1] expressed selectively by LC and DC using a subtractive cDNA cloning between J774 macrophages and XS DC lines established from the skin of newborn BALB/c mice [27] . XS cells closely mimic freshly isolated epidermal LC with many aspects including dendritic morphology, phenotype (CD45 + /Ia low /E-cadherin + /B7-1 -), cytokine and cytokine receptor expression, and APC capacity [28] . Dectin-2 is a type II-configurated transmembrane protein containing a carbohydrate recognition domain that is required for binding to specific carbohydrates [9, 12] . Encouraged by the DC-selective expression, we identified and characterized a 3.2 kb 5'-flanking region (Dec2FR) of the dectin-2 gene [6] . We found that Dec2FR contains unique promoter sequences that drive luciferase (Luc) gene expression, selectively in XS cells among non-DC lines and highest levels of Luc activity in epidermal LC among resting leukocytes (splenic DC, peritoneal macrophages, splenic B and T cells) prepared from a transgenic mouse line bearing a Dec2FR-*CORRESPONDENCE TO: BONKOBARA, M., Department of Veterinary Clinical Pathology, Nippon Veterinary and Animal Science University, 1-7-1 Kyonan-cho, Musashino-shi, Tokyo 180-8602, Japan.
driven Luc gene [6] . Thus, Dec2FR is a LC-targeted transcription unit that is likely to improve genetic immunization with respect to efficacy, fidelity, and probably safety.
To further characterize in vivo transcription activity of Dec2FR using the Dec2FR-Luc transgenic mice, we examined heterogeneity of LC in Dec2FR activity, other DC subset (dermal DC), and influences of leukocyte activation on LC-specificity of Dec2FR activity. Present study shows notable variation in Luc activity of LC isolated from different skin areas, detection of Dec2FR activity in dermal DC (but 8-fold lower than resting epidermal LC), and in vitro activation enhanced Dec2FR activity in leukocytes (but even highest levels are 6-fold lower than the resting LC). These results indicate that Dec2FR activity remains targeted to epidermal LC even after activation of leukocytes although degree of the specificity was decreased. Our study suggests high potency of Dec2FR as a transcription unit applicable to an epidermal LC-targeted gene expression system in vivo under normal and even inflammatory conditions.
MATERIALS AND METHODS

Monoclonal antibodies and reagents:
The monoclonal antibodies (mAb) specific for CD8, Mac-1, MHC class II I-A d /I-E d (2G9), CD45R/B220, CD3ε, CD11c, CD80, CD86 and Fc receptors (CD16/CD32, Fc III/II receptor) were purchased from Pharmingen (San Diego, CA). All chemical reagents used were obtained from Sigma (St. Louis, MO).
Generation of transgenic mice: Transgenic mice bearing a Dec2FR-driven Luc gene were generated as described previously [6] . Briefly, a plasmid vector (pDec2FR-Luc) DNA, containing a luciferase (Luc) gene under transcriptional control of a 5'-flanking region (nt +126 to -3176, corresponding to the nucleotides from the mRNA initiation site) of dectin-2 gene (Dec2FR), was depleted of its plasmid sequence by restriction enzyme digestion and purified by gel extraction. The purified DNA was microinjected into fertilized oocytes obtained from ICR mice. Transgenic founders with LC-specific Luc expression within the epidermis were selected and mated with wild-type ICR mice. The resulting mice (F2 offspring mice) were used at age of 4-20 weeks for all experiments. Mice were housed in the pathogen-free facility of the Animal Resource Center at the University of Texas Southwestern Medical Center. All the experiments were conducted according to guidelines of the National Institutes of Health.
Protein extraction from skin and Luc assays: Skin tissues were excised from various areas of three transgenic mice; ears, abdomens, footpads, and tails, pooled into one tube, and dissected into small pieces with a razor blade. Proteins were extracted from the skin by homogenization in 1 × cell lysis buffer (Promega, Madison, WI). An aliquot (5-10%) was used to measure Luc activities (expressed as relative light unit, RLU) determined by light emitted for 30 s with an Optocomp I Luminometer (MGM Instruments, Hamden, CT) using Luciferase Assay System (Promega). Protein concentration was quantified by the Bradford method, and their values were used to normalize Luc activity (RLU/µg).
Preparation of epidermal and dermal cells: Epidermal cells were prepared from various skin area (ear, abdomen, footpad, and tail) as described previously [5] . Briefly, skin specimens from four transgenic mice were pooled and floated on phosphate-buffered saline (PBS) containing 0.15% trypsin. After incubation at 37°C for 30-60 min, epidermal sheets were peeled off from the skin and treated with 0.3% trypsin-PBS at 37°C for 15 min with vigorous tapping. Epidermal cells detached from the epidermal sheets were passed through nylon mesh and collected.
Dermal cells were obtained by ex vivo culture of dermal sheets from ear skin as described previously [11] . Briefly, dermal sheet was prepared by removing epidermal sheets from skin by 0.15% trypsin-PBS treatment. After cutting into small pieces, they were cultured in complete Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (cDMEM) in 5% CO 2 incubator. After 3 days of culture, cells emigrated from the sheets were collected.
Purification of Ia + cells from epidermal and dermal cells: Depletion and purification of Ia
+ cells from epidermal and dermal cells were performed using immuno-magnetic beads, as described previously [6] , with minor modifications. Streptavidine-coated magnetic beads (Dynal Biotech, Lakesuccess, NY) were incubated with biotin-labeled rat anti-Ia mAb or with biotin-labeled rat IgG (an isotypic control) at room temperature for 30 min. Unbound mAb was removed by extensive washing of beads with PBS and finally resuspended in 50 µl of cDMEM. Epidermal or dermal cells were processed in three ways: one batch was left untreated (unfractionated), whereas the other two batches were incubated at 4°C for 1 hr with 2 × 10 7 of magnetic beads precoated with anti-Ia or an isotype IgG. Cells bound to beads were separated from unbound cells using magnetic apparatus. Unbound (depleted of Ia + cells) and bound (purified for Ia + cells) fractions were resuspended in 200 µl of PBS, and an aliquot (20 µl) was used for the cell counting. Protein was extracted from the rest of cells and 40% of the total extract assayed for Luc activity. The extent for depletion of Ia + cells was assessed by reduction in frequency of Ia + cells after treatment with the magnetic beads: Small aliquots of unfractionated cells (just before use of magnetic beads) and of a fraction not bound to anti-Ia or isotype IgG were stained with 10 µg/ml of FITC-conjugated anti-Ia or isotype IgG, followed by flow cytometry.
Purification of other leukocytes: DC, T cells, and B cells were purified from spleen as described previously [6] . Briefly, for DC, spleen cells were prepared from the same pool of transgenic mice as was used for preparing epidermal cell suspensions. After blocking Fc receptors with anti-FcR Ab, CD11c + spleen cells (DC) were purified using antiCD11c mAb-coated magnetic beads. T and B cells were isolated by flow cytometric sorting of spleen cells (2 × 10 6 ) stained with 10 µg/ml FITC-conjugated anti-CD3ε (T cells) or anti-B220 (B cells). For peritoneal macrophages, 4 days after intraperitoneal injection of 3% thioglycolate into trans-genic mice (3 mice/pool), peritoneal cells were collected from the mice and cultured for 3 days in 10% FCS-RPMI 1640 (cRPMI). After removing floating cells and weakly adherent cells by washing, peritoneal macrophages were harvested by scraping and examined for expression of Mac-1 and B220 to estimate contamination of peritoneal B cells (Mac-1 low /B220 + ) using flow cytometric analysis. Typically, the harvested cells comprise <10% of B cells. Cell counting and Luc assays were performed as described above. Selective isolation of DC, macrophages, T cells, and B cells was confirmed by flow cytometric analyses.
Activation of leukocytes: LC were treated as follows: Ear skin from five transgenic mice was dissected to dorsal and ventral sides and cultured in cDMEM containing LPS (10 µg/ml). After 3 days in culture, emigrated cells were purified of Ia + cells (LC) by using anti-Ia coated magnetic beads. For activation of splenic DC, spleen cells were cultured for 90 min in cDMEM and non-adherent cells removed. Adherent cells were then further cultured in the presence of LPS (10 µg/ml) for 2 days. DC were isolated from newly generated, floating cells using anti-CD11c coated magnetic beads.
Activation of peritoneal macrophages was performed by culturing in the presence of LPS (10 µg/ml) for 3 days in cDMEM. For T and B cell activation, spleen cells were divided into two batches and cultured with medium containing Concanavarin A (3 µg/ml) for T cells or LPS (10 µg/ml) for B cells. After culturing for 3 days in cRPMI, magnetic beads precoated with anti-B220 and anti-CD3 Ab isolated B and T cells, respectively.
Aliquots of cell suspensions just before immuno-bead purification were examined for activation status by determining surface expression levels of activation markers: CD86 for LC, DC, and B cells, and CD80 for macrophage. Activation of T cells was evaluated by increase in cellular bulk by flow cytometry.
RESULTS
Luc expression levels are highly variable in epidermal LC of different skin areas:
There are many DC subsets that express distinct surface markers and function [16] . This heterogeneity is thought to be generated by difference in precursors and DC-surrounding micro-environments (e.g., cytokines and adhesion molecules) [14 ,19] . Since epidermal structures and molecular compositions are quite different among skin area (e.g., ear and footpad skin) [18] , we speculate that dectin-2 expression or Dec2FR transcriptional activity may be variable in LC prepared from different skin areas. We thus examined Dec2FR transcription activity of epidermal cells isolated from various skin areas. Taking advantages of a transgenic mouse line bearing a Dec2FR-driven Luc gene, the transcription activity was expressed as Luc activity in a given mount of crude protein extract (RLU/µg) from various skin area (ear, abdomen, footpad, and tail) of the transgenic mice (a pool of 8 mice). Highest levels of Luc activity were found in extract from ear skin, at much lower levels in tail and footpad skin, and just above the background levels in abdominal skin (Fig. 1A) : The levels in ear skin were 41-fold greater than in abdominal skin. No endogenous Luc activity was detected in the extracts from all skin areas of control littermates. This large variation may be due to difference in the frequency of LC in the skin area or due to different degree of contamination with non-cellular proteins such as matrix proteins (normalization with protein amount over-estimates the number of cells). To test these possibilities, we assayed frequency of Ia + cells (LC) in epidermal cell suspension and Luc specific activity (RLU/cell) of LC purified from the cell suspensions. Flow cytometric analysis of Ia + cells showed no large difference in the frequency among all four-skin areas (Fig.  1B) : The frequency in ear (2.1%) was similar to the footpad (2.0%) and the abdominal skin (1.7%) and 3.5-fold higher than in the tail. These data are consistent with those previously reported by Bergstresser et al. using immuno-fluorescence staining of mouse skin with anti-Ia Ab [8] . We next assayed Luc expression levels in LC purified from three different skin areas (sufficient numbers of epidermal LC were not purified from tails). Epidermal cells prepared from three skin areas were separately incubated with anti-Ia Ab-coated magnetic beads, sorted into bead-bound (Ia + cells) and unbound (Ia-depleted cells) fractions and Luc specific activity (RLU/10 4 cell) determined (Fig. 1C) . High Luc activity was detected in bead-bound fractions from all three areas, but nearly background levels in unbound fractions, confirming our previous data that Dec2FR activity is specific to LC within epidermis. In experiment #1, Ia + cells (LC) in ear skin displayed highest Luc activity (121,749), 1.5-fold greater than in abdominal skin, and 10-fold than in footpad. Similar results were observed in the second set of experiments. These results suggest that low levels of Luc activity in abdominal skin (Fig. 1A) is most likely due to high degree of contamination with non-cellular proteins. Nonetheless, Dec2FR transcription activity is markedly variable dependently of skin area, suggesting heterogeneity of LC in dectin-2 gene expression.
Dermal Ia + cells express Luc activity: Previously we found highest levels of Luc activity in the skin among organs tested in the transgenic mice [6] . Most of this cutaneous activity (about 80%) is derived from the epidermis and the rest from the dermis. Since a DC subset also resides in the dermis, it is possible that dermal DC also express high levels of Luc activity. To examine the possibility, we purified dermal DC and assayed Luc specific activity (Fig. 2) . Dermal cells and epidermal cells (as control) were purified from dermal and epidermal sheets, respectively, prepared from ear skin of four mice. Dermal cells were purified of Ia + cells using anti-Ia immuno-beads and frequency of Ia + -cells in the unfractionated and bead-unbound cells determined by flow cytometric analysis ( Fig. 2A) . Unfractionated dermal cells showed 5.5% for Ia + cells, almost all of which were removed by treatment with anti-Ia Ab-beads (0.2% in the unbound fraction). By contrast, isotypic control IgG-coated beads did not affect the frequency, validating Ia-specificity in the immuno-bead fractionation. The purified Ia + cells showed markedly high Luc activity, compared to cells unbound to anti-Ia-beads (Fig. 2B) , indicating that the majority of dermal Luc activity was located to the Ia + cells (dermal DC). Although dermal Ia + cells (dermal DC) expressed higher Luc activity than splenic DC (Fig. 3) , the levels were approximately 5-fold lower than in epidermal Ia + cells (LC) purified from the same mice. Similar results were seen with a second experiment.
Dec2FR activity remains targeted to epidermal LC even after activation of leukocytes:
We have shown previously that Dec2FR transcription activity is highly targeted to epidermal LC among leukocyte subpopulations freshly isolated from untreated transgenic mice (under resting states). To address a question of whether activation of leukocytes influences the LC-specificity of Dec2FR activity, we treated leukocytes (LC, splenic DC, peritoneal macrophages, splenic T and B cells) with various stimuli. Epidermal cells containing LC were in vitro activated by LPS (10 µg/ml). Spleen cells enriched for DC, peritoneal cells for macrophages, and untreated spleen cells (for B cells) were also separately activated by LPS. Spleen cells (for T cells) were activated by Con A. These five leukocyte subpopulations were individually examined for surface expression of activation markers by flow cytometric analysis before purification: CD86 expression for MHC class II (Ia) + LC, CD11c + DC, and B220 + B cells and CD80 expression for Mac-1 high macrophages (Fig. 3) . Activation of CD3 + T cells was confirmed by increase in cellular bulk. Activated leukocytes were then purified using magnetic beads precoated with respective Ab or FACS sorting, followed by determination of Luc specific activity (RLU/cell). All five-leukocyte subpopulations induced up-regulated expression of respective activation marker following stimulation (Fig. 3A) . Dec2FR activity in epidermal LC decreased slightly following activation by LPS (8.6 RLU/cell in activation vs. 11.1 in resting, Fig. 3B) . By contrast, all other leukocytes displayed up-regulated Luc activity: greatest up-regulation was observed in activation of T cells (Luc activity in resting T cells was not detectable, but activated T cells showed levels similar to those by activated macrophages). Activated DC and macrophages showed 24-to 25-fold greater Luc activity than the respective resting cells. Activated B cells also showed up-regulation, but the Luc activity was just above background levels. However, these levels in activated leukocytes remained considerably low in a comparison to resting LC (Fig. 3B) , indicating that Dec2FR retains LC-targeting activity even following activation of leukocytes.
DISCUSSION
Previously we showed that constitutively high levels of Dec2FR activity is found in a XS52 DC line and in epidermal LC of a transgenic mouse line bearing a Dec2FR-driven Luc gene. This previous study revealed that Dec2FR activity is highly targeted to epidermal LC among resting leukocytes, indicating a high potential of Dec2FR to drive gene expression in a LC-specific manner. Presently, we further characterized transcriptional activity of Dec2FR in DC subsets and its regulation under resting and activated states of leukocytes. We found that Dec2FR activity is highly variable in LC isolated from different skin areas (Fig. 1) and that dermal DC express high levels of Dec2FR activity but still lower levels than resting LC (Fig. 2) . We also indicated that activation affected Dec2FR activity remarkably in leukocytes other than LC (Fig. 3) . Altogether, our study indicates that Dec2FR is a transcription unit capable of initiating transcription of its down-stream gene at high levels in epidermal LC of mouse even under activation status. We thus consider this promoter to be utilized to genetically manipulate gene expression in epidermal LC in vivo simply by topical application of DNA to skin and even in inflammatory skin.
We showed that Dec2FR activity is highly variable in LC purified from various skin areas, with highest activity in LC of ear skin and lowest in those of abdominal skin. Since LC frequency in each skin area is similar, this finding suggests that Dec2FR activity is regulated by micro-environmental factors (e.g., cytokines and adhesion molecules) produced by different structures of skin areas (e.g., thickness of dermis and corneum). An alternative interpretation is that Dec2FR activity is expressed by certain subset of LC, the frequency of which may be highest in ear skin. This notion fits the current concept that human epidermal LC can be sorted into two subsets with distinct phenotypes (CD1a + / HLA-DR low and CD1a + /HLA-DR high ) [21] . Unfortunately, we could not address an issue of whether epidermal Ia + cells contain cells expressing Dec2FR activity and those not expressing because anti-luciferase Ab failed to detect luciferase expression in LC using immuno-histochemistry.
Our previous data that epidermal LC express much greater activity of Dec2FR than splenic DC raised a possibility that Dec2FR activity is a marker to distinguish LC from other DC subsets, like other markers (e.g., E-cadherin). In this study, we examined Dec2FR activity in one of DC subsets, dermal DC, because previous study showed that skin shows highest levels of Dec2FR activity among mouse organs, 80% of which is located to the epidermis and the remaining 20% to the dermis (this activity is yet higher than in other organs). Dermal DC also expressed high levels of Luc activity, 30-fold higher than splenic DC, but 5-fold lower than resting LC (Fig. 2) . Importantly, most of Luc activity in dermis is exclusively located to dermal Ia + cells. Thus we conclude that Dec2FR activity is constitutively expressed not only by epidermal Ia + cells (LC) but also by dermal Ia + cells (dermal DC). These cutaneous high levels of Dec2FR activity is not predetermined at the precursor levels because dermal DC and epidermal LC developed from different origins (dermal DC and epidermal LC from monocytes and myeloid cells, respectively [17] ). Rather, it is likely due to activation of Dec2FR promoter in the cutaneous environments during development of DC precursors after homing. Alternatively, it may be possible to speculate that Dec2FR activity is expressed by mature LC and also by their precursors that are assumed to reside in the dermis [23] .
We also examined influence of leukocyte activation on Dec2FR activity. In vitro activation up-regulated remarkably Dec2FR activity in all leukocyte subpopulations tested, except LC and probably B cells. Greatest up-regulation was observed with T cells. This is most likely due to IFNγ, which produced by activated leukocytes, that activates Dec2FR activity through a cis-acting transcriptional element (an IFNγ-responsive element) [10] responsible for IFNγ-dependent gene activation (Dec2FR contains the element) [6] . IFNγ may be responsible for notable up-regulation of Dec2FR activity in activated DC because DC were purified after stimulating DC-enriched splenic cells with LPS, which should contain T cells. However, this IFNγ-dependent activation of Dec2FR activity may not apply to the up-regulation in activated macrophages (no reports demonstrating production of IFNγ by peritoneal cells). With respect to LC, failure of activated LC to enhance Luc activity may be accounted for by inability of activated LC to produce IFNγ. Our preliminary study did not support this notion: Treatment of LC with IFNγ failed to induce up-regulation of Luc activity (data not shown). Taken together, up-regulation of Dec2FR may be achieved through IFNγ and/or another factors. Moreover, in another pilot study, we found that ultraviolet B (UVB) significantly up-regulates Dec2FR activity in LC (data not shown). Although the mechanisms of this up-regulation are not disclosed yet, UVB inducible transcription factors such as AP1 may also be involved in the regulation of Dec2FR activity.
Improvement of efficacy in the genetic vaccination is an important issue to better maintain human and animal health. As mentioned in the Introduction, one of promising strategies is to target gene expression to APC. In this regard, a Dec2FR-driven, epidermal LC-targeted gene expression system appears to be a best candidate to date, compared to other gene promoters used for gene expression studies in animals (refer to detail discussions in our previous report [6] ). Having shown Dec2FR activity to highly target to epidermal LC, we anticipate that our LC-targeting gene expression system provides opportunities to improve genetic vaccination with respect to not only efficacy but also with fidelity and presumably safety. A Dec2FR-driven gene can be introduced directly into the epidermis via gold particle-(gene gun) [24] or ultrasound-mediated gene transfer methods [15] , in which only epidermal LC will express antigens, eventually leading to activation of antigen-specific T cells. This gene deliver eliminates the requirement of large numbers of syngeneic DC in the DC-based vaccination and is likely to decrease potential risks of carcinogenesis induced by integration of foreign DNA to host chromosomes because Dec2FR nucleotides are derived from host genome and because DNA-transfected keratinocytes, a major cell type in the epidermis, die within approximately one month (for human) during the self-renewal.
Our present study expanded our basic knowledge regarding Dec2FR activity and its regulation and thus led us to apply our LC-targeted gene expression system to genetic vaccination to domestic animals. As a first step, we have already isolated a mouse Dec2FR-corresponding region from cattle chromosomes and are presently establishing a LC-targeted gene expression system for cattle.
